Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

Product sales rose 11%, led by 14% volume growth. Products including Repatha, Blincyto and Tezspire all posted at least double digit sales growth, the company said. For the current year, Amgen expects ...

Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

Amgen's sales of its seven innovative products posted ... and improving balance sheet. That's why the Quant System anticipates 6.8% annual forward dividend growth. For more perspective, this ...

That was fueled by double-digit sales growth from 10 of its products ... Amgen’s Dividend Is Safe and the Balance Sheet Is Improving Amgen’s 3.4% dividend yield registers at twice the ...

Amgen’s second quarter revenues were down 3% as competition pegged back its off-patent drugs Sensipar and Neulasta, but still came in ahead of analyst expectations. Total revenues of $5.87 ...

Amgen's balance sheet has slightly improved ... but when excluding the impact of the acquisition, product sales still grew 8% with volume growth of 12%. Operating income increased slightly ...